Using a deal with CAR-T frontrunner Kite Pharma Inc. as a springboard, San Francisco-based start-up Cell Design Labs hopes to bring forward a new generation of specific, reversible T-cell therapies as an alternative to the imprecise, explosive nature of the candidates tested to date.
Kite Pharma, Juno Therapeutics Inc. and Novartis AG have been at the forefront of development for chimeric antigen receptor T-cell (CAR-T) therapies, and Kite is poised to bring the first product to market with plans to submit KTE-C19 for accelerated approval to treat advanced forms of non-Hodgkin lymphoma by the end of the year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?